Drug intelligence / Profile preview

il-10ra blocking antibody

Development stage
Preclinical
Lead developer
University of Bordeaux
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intraperitoneal
01

Overview

An IL-10RA blocking antibody is a monoclonal antibody designed to bind to the Interleukin-10 receptor subunit alpha (IL-10RA), thereby inhibiting the signaling of the immunosuppressive cytokine IL-10. In the context of oncology, particularly in primary cutaneous diffuse large B-cell lymphoma (PCDLBCL-LT), IL-10 secreted by tumor cells induces an immunosuppressive M2-like phenotype in tumor-associated macrophages (TAMs). By blocking the IL-10/IL-10RA axis, these antibodies can reverse macrophage-mediated immunosuppression, enhance T-cell activity, and potentially sensitize tumor cells to chemotherapy. Research presented at ASH 2025 indicates that IL-10RA blockade can fully reverse the phenotypic changes induced by PCDLBCL-LT cells on macrophages, suggesting a potential therapeutic vulnerability in this disease.

Other names
anti-IL-10RA antibodyanti-IL10RA antibodyanti-IL 10RA antibodyIL-10 receptor alpha blockerIL10 receptor alpha blockerIL 10 receptor alpha blocker
02

Targets

IL10RA (Interleukin-10 Receptor)

Beyond the preview

Go deeper on il-10ra blocking antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on il-10ra blocking antibody.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call